GlycoMimetics, Inc.

NasdaqGM:GLYC Stock Report

Market Cap: US$181.8m

GlycoMimetics Management

Management criteria checks 4/4

GlycoMimetics' CEO is Harout Semerjian, appointed in Aug 2021, has a tenure of 2.58 years. total yearly compensation is $1.43M, comprised of 42.8% salary and 57.2% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth $70.50K. The average tenure of the management team and the board of directors is 2.6 years and 7.5 years respectively.

Key information

Harout Semerjian

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage42.8%
CEO tenure2.6yrs
CEO ownership0.04%
Management average tenure2.6yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 21

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Mar 20
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Jan 30

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Nov 19
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Jan 30
Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

Oct 06
Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics has a new Chief Medical Officer

Sep 06

GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K

Aug 03

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

Jun 04
GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

Mar 16

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Nov 20
Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Aug 20
We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

May 26

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12
Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

GlycoMimetics EPS beats by $0.04

May 03

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19
GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24
GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28
How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease

Dec 07

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Dec 07
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

The Investment Case For GlycoMimetics

Nov 17

CEO Compensation Analysis

How has Harout Semerjian's remuneration changed compared to GlycoMimetics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$38m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$1mUS$614k

-US$47m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$64m

Dec 31 2021US$3mUS$244k

-US$63m

Compensation vs Market: Harout's total compensation ($USD1.43M) is about average for companies of similar size in the US market ($USD1.47M).

Compensation vs Earnings: Harout's compensation has been consistent with company performance over the past year.


CEO

Harout Semerjian (53 yo)

2.6yrs

Tenure

US$1,434,922

Compensation

Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...


Leadership Team

NamePositionTenureCompensationOwnership
Harout Semerjian
CEO, President & Director2.6yrsUS$1.43m0.039%
$ 70.5k
Rachel King
Co-Founder & Director21.2yrsUS$235.67k0.98%
$ 1.8m
Brian Hahn
Senior VP & CFO12.2yrsUS$918.19k0.056%
$ 101.2k
Stephanie Irish
Vice President of Accounting5.2yrsno datano data
Christian Dinneen-Long
General Counsel & Company Secretary4.9yrsno datano data
Bruce Johnson
Senior VP & Chief Commercial Officer2.1yrsno data0.22%
$ 391.9k
Edwin Rock
Senior VP & Chief Medical Officer1.5yrsno data0.58%
$ 1.1m
Chinmaya Rath
Senior VP & Chief Business Officer1.2yrsno data0.25%
$ 454.5k
Shantha Tyavanagimatt
Senior Vice President of Technical Operationsless than a yearno datano data

2.6yrs

Average Tenure

53yo

Average Age

Experienced Management: GLYC's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Harout Semerjian
CEO, President & Director2.6yrsUS$1.43m0.039%
$ 70.5k
Rachel King
Co-Founder & Director21.2yrsUS$235.67k0.98%
$ 1.8m
Daniel Junius
Independent Director8yrsUS$71.74k0.14%
$ 263.0k
Timothy Pearson
Independent Chairman of the Board10yrsUS$91.24k0.038%
$ 69.5k
Scott Koenig
Independent Director7yrsUS$53.74k0.057%
$ 103.6k
Scott Jackson
Independent Director5.3yrsUS$64.24k0.0081%
$ 14.8k
Patricia S. Andrews
Independent Director6.8yrsUS$58.24k0.091%
$ 165.3k
Mark A. Goldberg
Independent Director9.7yrsUS$64.24k0.049%
$ 89.5k

7.5yrs

Average Tenure

64yo

Average Age

Experienced Board: GLYC's board of directors are considered experienced (7.5 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.